Details

Targeting estrogen metabolism in high-grade serous ovarian cancer shows promise to overcome platinum resistance
ID Marolt, Nika (Author), ID Pavlič, Renata (Author), ID Kreft, Tinkara (Author), ID Gjorgoska, Marija (Author), ID Lanišnik-Rižner, Tea (Author)

.pdfPDF - Presentation file, Download (5,12 MB)
MD5: 6AB0EFCF6CE9640E85B4636508CBA1C3
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S0753332224009533 This link opens in a new window

Abstract
The high mortality rate due to chemoresistance in patients with high-grade ovarian cancer (HGSOC) emphasizes the urgent need to determine optimal treatment strategies for advanced and recurrent cases. Our study investigates the interplay between estrogens and chemoresistance in HGSOC and shows clear differences between platinum-sensitive and -resistant tumors. Through comprehensive transcriptome analyzes, we uncover differences in the expression of genes of estrogen biosynthesis, metabolism, transport and action underlying platinum resistance in different tissues of HGSOC subtypes and in six HGSOC cell lines. Furthermore, we identify genes involved in estrogen biosynthesis and metabolism as prognostic biomarkers for HGSOC. Additionally, our study elucidates different patterns of estrogen formation/metabolism and their effects on cell proliferation between six HGSOC cell lines with different platinum sensitivity. These results emphasize the dynamic interplay between estrogens and HGSOC chemoresistance. In particular, targeting the activity of steroid sulfatase (STS) proves to be a promising therapeutic approach with potential efficacy in limiting estrogen-driven cell proliferation. Our study reveals potential prognostic markers as well as identifies novel therapeutic targets that show promise for overcoming resistance and improving treatment outcomes in HGSOC.

Language:English
Keywords:high-grade serous ovarian cancer, estrogen metabolisem, prognostic biomarkers, therapeutic targets, transcriptomic analysis, chemoresistance
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2024
Number of pages:17 str.
Numbering:Vol. 177, art. 117069
PID:20.500.12556/RUL-166742 This link opens in a new window
UDC:577.2
ISSN on article:1950-6007
DOI:10.1016/j.biopha.2024.117069 This link opens in a new window
COBISS.SI-ID:202256387 This link opens in a new window
Publication date in RUL:23.01.2025
Views:603
Downloads:161
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Biomedicine & pharmacotherapy
Shortened title:Biomed. pharmacother.
Publisher:Éditions scientifiques et médicales Elsevier
ISSN:1950-6007
COBISS.SI-ID:23136261 This link opens in a new window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:serozni rak jajčnikov visoke stopnje, metabolizem estrogena, prognostični biomarkerji, terapevtske tarče, transkriptomska analiza

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P3-0449
Name:Translacijska molekularna endokrinologija za zdravje žensk

Funder:ARRS - Slovenian Research Agency
Funding programme:Young researchers

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back